In addition to glycolysis, the oncogenic transcription factor c-MYC (MYC) stimulates glutamine catabolism to fuel growth and proliferation of cancer cells through up-regulating glutaminase (GLS). Glutamine is converted to glutamate by GLS, entering the tricarboxylic acid cycle as an important energy source. Less wellrecognized, glutamate can also be converted to proline through Δ 1 -pyrroline-5-carboxylate (P5C) and vice versa. This study suggests that some MYC-induced cellular effects are due to MYC regulation of proline metabolism. Proline oxidase, also known as proline dehydrogenase (POX/PRODH), the first enzyme in proline catabolism, is a mitochondrial tumor suppressor that inhibits proliferation and induces apoptosis. MiR-23b* mediates POX/PRODH down-regulation in human kidney tumors. MiR-23b* is processed from the same transcript as miR-23b; the latter inhibits the translation of GLS. Using MYC-inducible human Burkitt lymphoma model P493 and PC3 human prostate cancer cells, we showed that MYC suppressed POX/PRODH expression primarily through upregulating miR-23b*. The growth inhibition in the absence of MYC was partially reversed by POX/PRODH knockdown, indicating the importance of suppression of POX/PRODH in MYC-mediated cellular effects. Interestingly, MYC not only inhibited POX/PRODH, but also markedly increased the enzymes of proline biosynthesis from glutamine, including P5C synthase and P5C reductase 1. MYCinduced proline biosynthesis from glutamine was directly confirmed using 
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amino acids | redox signaling | reactive oxygen species | miRNA | metabolic tumor suppressor G rowing tumors alter their metabolic profiles to meet the bioenergetic and biosynthetic demands of increased cell growth and proliferation (1) (2) (3) . Many oncogenes and tumor suppressors have been linked to tumor metabolic regulation (4, 5) . Proline oxidase, also known as proline dehydrogenase (POX/PRODH), as a mitochondrial inner membrane enzyme is involved in the first step of proline catabolism and has been identified as one of a few mitochondrial tumor suppressors (6) (7) (8) (9) (10) . The gene encoding POX/PRODH also known as PRODH was initially identified as a p53-induced gene in a screening study (8) . Here, we will refer to this enzyme as POX/PRODH and to the gene as PRODH. Intensive investigation has led to the recognition of important functions of proline metabolism in human tumors. Earlier work in our laboratory has demonstrated the important roles of POX/PRODH in the apoptosis induced by cytotoxic agents and by peroxisome proliferator activated receptor γ (PPARγ) and its ligands (6, 10) . Hyperexpression of POX/PRODH in cancer cells is sufficient to initiate apoptosis because of its ability to generate reactive oxygen species (ROS) (6, 7) . In addition to inducing apoptotic cell death, POX/ PRODH negatively regulates the growth of various cancer cells, causes cell cycle arrest at the G 2 -M checkpoint, and inhibits tumor formation in a mouse xenograft model (7, 9) . Subsequently, the absence or reduction of POX/PRODH was observed in a variety of human tumor tissues compared with their normal tissue counterparts (9, 11) , and miR-23b* was found to be one of the mechanisms mediating POX/PRODH down-regulation in renal tumors (11) .
The MYC oncogene is frequently dysregulated in human cancers. It encodes a transcription factor, c-MYC (herein termed MYC), which links altered cellular metabolism to carcinogenesis. In addition to its known function in regulating glucose metabolism (12) , MYC recently has been documented to induce the expression of mitochondrial glutaminase (GLS) to stimulate glutamine catabolism (13, 14) . The importance of glutamine catabolism in cancer cell metabolism was reemphasized by these findings. In addition to its use for synthesis of proteins, nucleotides, and lipids (15, 16) , glutamine is converted to glutamate by GLS. Glutamate not only is an essential component of glutathione, but also an important energy source via anaplerotic input into the tricarboxylic acid (TCA) cycle after conversion to α-ketoglutarate (α-KG). Less well-recognized, glutamate can also be converted to proline through Δ 1 -pyrroline-5-carboxylate (P5C) catalyzed sequentially by P5C synthase (P5CS) and P5C reductase (PYCR) (Fig. 1A) . Conversely, proline can be converted to glutamate through proline catabolism sequentially catalyzed by POX/ PRODH and P5C dehydrogenase (P5CDH). The proline-derived glutamate can be further converted to α-KG, or used to generate glutamine through glutamine synthetase (GS). Thus, we wondered whether oncogenic MYC could affect proline metabolism and, specifically, modulate proline catabolism by the tumor suppressor POX/PRODH. In this study, we investigated the effects of MYC on proline catabolism and proline biosynthesis from glutamine, especially its effect on the expression of POX/PRODH and its regulatory mechanisms. The contribution of POX/PRODH to MYC-mediated tumor cell behavior was further established.
Results

MYC Robustly
Suppresses the Expression of POX/PRODH Protein. To investigate whether MYC plays a role in the regulation of POX/ PRODH expression in human cancer, we used human Burkitt lymphoma model P493 cells that bear a tetracycline-repressible MYC construct. In the absence of tetracycline, ectopic MYC is induced in a tumorigenic state that resembles human Burkitt lymphoma. We analyzed the changes of POX/PRODH protein and mRNA expression in response to MYC. As shown in Fig. 1B , POX/PRODH protein increased in a time-dependent fashion and reached approximately 3.8-fold and 7.5-fold when P493 cells were treated with tetracycline for 24 h and 120 h, respectively. When MYC expression was recovered by tetracycline removal, the POX/ PRODH protein diminished markedly (Fig. 1D) . However, POX/ PRODH mRNA did not show any obvious increase until 72 h after tetracycline treatment (∼1.7-fold), and even at 120 h, it increased only ∼4.7-fold ( Fig. 1 C and E) . Thus, the changes of POX/ PRODH mRNA levels were delayed and plateaued at a lower level compared with changes in POX/PRODH protein levels.
Because overexpression of MYC was also found in human prostate cancer, we tested whether MYC had the same effects on the expression of POX/PRODH in the PC3 human prostate cancer cells. MYC knockdown in PC3 cells by short interfering RNA (siRNA) resulted in the inhibition of POX/PRODH expression with a pattern similar to the P493 cells (Fig. S1A) . When MYC was knocked down 85%, POX/PRODH protein expression increased ∼4.2-fold, whereas POX/PRODH mRNA levels only increased ∼1.6-fold (Fig. S1 A and B) .
POX/PRODH Suppression Is Essential for MYC-Mediated Cancer Cell
Proliferation and Survival. As mentioned above, POX/PRODH has been identified as a tumor suppressor, whose expression is suppressed in a variety of tumors; it induces apoptosis through the generation of ROS and inhibits tumor growth in a xenograft mouse model. Whether the suppression of POX/PRODH by MYC is functionally linked to MYC-induced proliferation and cell survival became an interesting question. We knocked down the expression of POX/PRODH by siRNA in P493 cells with MYC suppressed by tetracycline. Western blot confirmed the knockdown of POX/PRODH ( Fig. 2A) . In Fig. 2B , at different time points of tetracycline treatment, POX/PRODH siRNA consistently reduced the production of ROS, although the suppression of MYC by tetracycline decreased the accumulation of ROS at day 4 (-Tet + siNeg vs. +Tet + siNeg as shown in Fig.  2B ), which may reflect the different effects of various MYC regulated genes on ROS production at various stages (17) (18) (19) . Correspondingly, the apoptosis assay by flow cytometry showed that knockdown of POX/PRODH by siRNA decreased the percentage of apoptotic and dead cells occurring with MYC suppression (Fig. 2C) . In contrast, the number of living cells suggested that POX/PRODH siRNA could significantly rescue 30∼40% of the diminished growth rates, which were 46% and 82% at day 2 and day 4, respectively, resulting from MYC suppression by tetracycline (Fig. 2D ). These results indicated that POX/PRODH suppression participates in MYC-mediated cancer cell proliferation and survival.
To extend the above conclusion from the tetracycline-controlled cells to cancer cells overexpressing MYC, we performed the same assays in PC3 prostate cancer cells. We first confirmed the decreased expression of MYC and POX/PRODH by their respective siRNAs using Western blots (Fig. S2A ). As shown in Fig. S2B , knockdown of MYC by siRNA first resulted in the decrease of ROS production at 3 d followed by a small increase at 6 d. When POX/PRODH siRNA was used to reduce the increased expression of POX/PRODH resulting from MYC siRNA, the production of ROS was decreased at both time points. The reduction of MYC by MYC siRNA reduced cell growth 53.0% and 68.6% at 3 and 6 d, respectively, which could be recovered 19.5% and 71.6% by POX/PRODH siRNA ( POX/PRODH mRNA levels were measured by real-time RT-PCR using GAPDH as an internal control. The relative folds were calculated to the group without tetracycline treatment. The results shown are mean ± SEM, n = 3. P values were obtained by one-way analysis of variance. *P < 0.05 and **P < 0.001 compared with 0 h control.
cells increased threefold with MYC siRNA, which was decreased ∼40% by POX/PRODH knockdown (Fig. S2D) . The mechanism about ROS production by POX/PRODH through complex III of the electron transport chain, and the contribution of ROS generated by POX/PRODH to reduced growth resulting from MYC suppression are described in SI Results and Discussion and shown in Fig. S3 .
MYC Indirectly Suppresses POX/PRODH Expression at the Transcriptional Level. As described above, MYC decreased POX/PRODH mRNA expression although it was not comparable with its inhibition of POX/PRODH protein levels. To further confirm its regulation of POX/PRODH transcription, we tested the effect of MYC on PRODH promoter activity in PC3 prostate cancer cells by transfecting the PRODH promoter/luciferase reporter construct containing PRODH promoter region (10) . As shown in Fig. 3A , knockdown of MYC resulted in the increase of PRODH promoter activity, indicating MYC regulates POX/PRODH at the transcriptional level. However, it is unknown whether MYC acts as a transcription factor by binding directly to the PRODH promoter area. Analysis of PRODH promoter nucleotide sequence revealed one canonical MYC binding site 5′-CACGTG-3′ (E-box) and one noncanonical binding site (5′-ACGGTG-3′) at −2808 to −2813 bp and −637 to −642 bp of the PRODH promoter region, respectively. To investigate whether MYC binds directly to the PRODH gene, we performed the chromatin immunoprecipitation (ChIP) assay in P493 cells, using cyclindependent kinase 4 (CDK4), which has been reported to be up-regulated by MYC (20) , as a positive control. None of the PRODH promoter regions containing either canonical or noncanonical MYC binding sites showed significant PCR amplification (Fig. 3B) , demonstrating that MYC does not directly interact with the PRODH gene, and the decreased POX/ PRODH mRNA expression may be mediated through other transcription factors. This result is consistent with the delayed changes of POX/PRODH mRNA levels regulated by MYC as showed in Fig. 1 .
MYC Suppresses POX/PRODH Protein Expression Primarily Through
Increasing miR-23b*. The above data showed that POX/PRODH protein, but not mRNA, robustly responds to the alteration of MYC levels in P493 and PC3 cells. Thus, we sought regulatory effects of MYC on POX/PRODH at the posttranscriptional level. Earlier study showed that MYC suppresses the expression of miR-23b in P493 and PC3 cells (14) . Our previously published study indicated that miR-23b* mediates the loss of POX/PRODH protein in renal cancers (11) . Because miR-23b and miR-23b* originate from the same transcript, we first determined the effects of MYC on miR-23b* and then tested whether the suppression of POX/PRODH by MYC was related to its effects on miR-23b* in P493 cells. In Fig. 4 A and B, real-time PCR assays showed that miR-23b* levels decreased with diminished MYC expression and then increased on MYC reinduction in a manner compatible with the POX/PRODH protein levels observed in Fig. 1 B and D. PC3 prostate cancer cells also showed the same relationship between MYC and the levels of miR-23b*, i.e., MYC knockdown by siRNA resulted in the decrease of miR-23b* expression (Fig. S4A) . These results were distinct from the reported decrease of miR-23b by MYC. The nonparallel expression of the sibling miRNAs regulated by MYC implied that MYC may differentially affect the processing of miRNA, including their stabilization and degradation. SI Results and Discussion and Fig. S5 provide the preliminary data that showed that MYC regulated the differential expression of miR-23b* and miR-23b partially through up-regulating Agonaute 2 protein (Ago 2), a key player in miRNAs stability and degradation.
To assess whether the suppression of POX/PRODH by MYC relates to the increase of miR-23b*, we transfected P493 cells with antagomirs against miR-23b* to inhibit the high expression of miR-23b* induced by MYC overexpression in the absence of tetracycline. As shown in Fig. 4C , POX/PRODH protein level increased 1.5-fold after miR-23b* was inhibited by antagomirs. Additionally, we transfected P493 cells with mimic miR-23b* under MYC inhibition by tetracycline. Ectopic miR-23b* expression at high levels was confirmed by real-time PCR after the transfection. As expected, mimic miR-23b* resulted in a marked decrease in POX/PRODH protein (Fig. 4D) . However, the decrease of POX/PRODH still was not comparable with that without tetracycline treatment, indicating that MYC could suppress POX/PRODH expression through pathways other than miRNA, such as the indirect regulation at the transcriptional level as shown above.
We further confirmed the suppression of POX/PRODH by MYC through miR-23b* in PC3 cells by transfecting the luciferase reporter with the POX/PRODH mRNA 3′ UTR sequence containing the miR-23b* binding site, designated as pPOX 3′ UTR (11) . pMIR-Report, the original reporter without the POX/PRODH mRNA 3′ UTR was used as a control. Negative siRNAs (siNeg) or MYC siRNAs (siMYC) were cotransfected into PC3 cells. As shown in Fig. S4B , MYC knockdown by siRNAs increased luciferase activity of pPOX 3′ UTR significantly, indicating the decrease of miR-23b* by siMYC. As expected, without MYC knockdown, the luciferase activity of pPOX 3′ UTR was much lower than that of the original pMIR-Report because of high levels of miR-23b* binding to POX/PRODH mRNA 3′ UTR, thereby suppressing luciferase expression.
MYC Markedly Increases the Biosynthesis of Proline from Glutamine.
MYC has been shown to enhance GLS expression and glutamine catabolism (13, 14) . Because glutamine and proline are interconvertible (Fig. 1A) , we investigated the MYC regulation of glutamine and proline metabolism by studying the enzymes of glutamine-proline metabolic pathway in P493 cells. As shown in Fig. 5A , MYC robustly increased the expression of GLS, P5CS, and PYCR1 in the pathway from glutamine to proline and decreased the expression of POX/PRODH, P5CDH, and GS in the pathway from proline to glutamine. PC3 human prostate cancer cells displayed the same correlation between MYC and glutamine and proline metabolism. The reduction of MYC by MYC siRNA resulted in the increase of POX/PRODH, P5CDH, and GS and decrease of GLS, P5CS, and PYCR1 (Fig. 5B) . We then measured the intracellular levels of proline in P493 MYC-On and MYC-Off cells. As expected, MYC dramatically increased the intracellular levels of proline (Fig. 5C) .
To confirm directly the production of proline from glutamine induced by MYC, we traced the conversion of glutamine to proline by gas chromatography-mass spectrometry (GC-MS), Fourier transform-ion cyclotron resonance MS (FT-ICR-MS), and NMR using [U- 13 C, 15 N]-glutamine (Gln) as a tracer in P493 cells. Glutamine was labeled at all five carbon and both nitrogen atoms, which were incorporated into newly synthesized proline. Fig. 5D shows the expected labeling patterns from [U- 13 C, 15 N]-Gln, including the intermediates of the TCA cycle and proline (Pro) via glutamate (Glu). As described in detail (21) , MYC induced glutamine oxidation via the TCA cycle such that all of the intermediates of the TCA cycle derived from glutamine were increased by MYC, including α-KG, succinate, fumarate, malate, and citrate. To confirm the previous results, the GC-MS analysis of 13 C, 15 N-Gln contribution to citrate in P493 cells with MYCOn and MYC-Off is shown in Fig. 5E . The production of 13 C 5 -citrate (m+5) from Gln tracer can be explained by the reductive carboxylation of α-KG, which entails a reversal of the citrate to α-KG reaction catalyzed by aconitase and isocitrate dehydrogenase (IDH) as recently reported in other cells (22) (23) (24) (25) . However, this process is unlikely to be the major pathway in P493 cells under normoxia, as discussed (21) . This finding is also consistent with the recent reports that showed the glutaminedependent reductive carboxylation is most prevalent either under hypoxia or in cells with a TCA cycle deficiency (23) (24) (25) . Fig. 5F shows the GC-MS analysis of 13 C, 15 N-Gln contribution to proline synthesis with or without tetracycline treatment. m+1 to m+6 represent incremental increases of neutron masses resulting from one to five 13 C and zero or one 15 N incorporation into proline. Thus, the m+6 labeled species of proline ( 13 C 5 , 15 NPro) is the direct product from 13 C 5 , 15 N 2 -Gln catabolism, whereas the rest of the labeled species can be derived from the parent glutamine tracer via metabolic scrambling through the TCA cycle, transamination (TA), and/or glutamate dehydrogenase (GDH) activity (Fig. 5D) . The increased expression of MYC with tetracycline withdrawal markedly and consistently increased the levels of m+1 to m+6 isotopologues of proline, although the ratios of concentrations for the various labeled isotopologues of proline were not constant. The nonconstant ratios of proline isotopologues between MYC On and MYC Off are likely due to the following reasons. As stated above, the various labeled species of proline except for m+6 can be derived from the various carbon and nitrogen scrambling processes through the TCA cycle, transamination, and/or GDH activity, as shown in Fig. 5D after three turns. Scrambling of carbon detected in proline via the TCA cycle is consistent with the production of labeled citrate with different scrambled labeling patterns (e.g., m+2 and m+4 isotopologues in Fig. 5E ). The m+2 and m+4 isotopologues of citrate are the respective products of three and one turn of the Krebs cycling (Fig. 5D ), whereas the m+5 ( 13 C 5 -citrate) and m+6 ( 13 C 6 -citrate) can be contributed from pyruvate carboxylation and TCA cycle-independent ATP citrate lyase plus malic enzyme reaction sequence as shown in Le et al. (21) . MYC suppression may have differential effects on these processes. Moreover, the abundant m+5 isotopologue of Pro implies the replacement of 15 N by 14 N as all five carbons should be labeled because of the high abundance of its precursor 13 C 5 -Glu (21) . The FT-ICR-MS analysis in Fig. S6 showed the fractional distribution of Glu, aspartate (Asp) and proline isotopologues. Consistent with that of proline, 13 C and 15 N isotopologue distributions of Glu and Asp were differentially modulated by MYC expression.
In addition, the NMR spectral analysis in Fig. S7 showed the extensive 13 C enrichment in proline from glutamine induced by MYC, which further confirmed the GC-MS data. These findings are consistent with the marked increases in the enzymes mediating proline synthesis from glutamate. Thus, MYC not only stimulates the conversion of glutamine to glutamate, but also markedly enhances subsequent conversion of glutamate to proline via proline biosynthetic enzymes.
Discussion
As the only proteinogenic secondary amino acid, proline is metabolized by its own family of enzymes that respond to various stresses and participate in redox regulation and metabolic signaling. Recent studies defining the regulation of this system suggest that proline is a "stress substrate" and proline metabolism may be a potential antitumor target. POX/PRODH, the first enzyme in proline catabolism, is induced by genotoxic (p53) (8) , inflammatory (PPARγ and its ligands) (10) , and nutrient stress (glucose deprivation) (26) . Proline catabolism catalyzed by POX/ PRODH generates electrons to produce ROS and initiates a variety of downstream effects, including blockage of the cell cycle and initiation of apoptosis. In this sense, POX/PRODH functions as a metabolic tumor suppressor, which is supported by its low expression or loss in tumors and the inhibition of tumor formation in a mouse xenograft tumor model by its ectopic expression. In this work, we showed that oncogenic transcription factor MYC inhibits POX/PRODH expression and, thereby, inhibits its tumor suppressor function. When MYC is suppressed, the increase of POX/PRODH induces ROS generation and apoptosis, leading to decreased cell proliferation and growth. These results suggest that MYC-induced suppression of POX/ PRODH contributes to MYC-mediated changes of cell behavior including proliferation and metabolic reprogramming that, in turn, contributes to tumorigenesis and tumor progression.
Transformed cells from different origins typically up-regulate both glucose and glutamine consumption as sources of metabolic energy and as precursors for biosynthesis of macromolecules (13, 27) . The MYC oncogene, which plays a critical role in many human cancers, is considered a master regulator of cell metabolism and proliferation. It not only promotes glucose uptake and induces aerobic glycolysis, but also enhances glutamine uptake and stimulates glutamine catabolism. As mentioned above, glutamine metabolism is linked to biosynthesis of protein, nucleotide N]-Gln contribution to citrate and proline synthesis in P493 cells with MYC On and Off. All GC-MS data were corrected for natural abundance isotopic contribution and normalized to cell pellet wet weight. Each value is an average of duplicate samples. The entire experiment was repeated three times.
and lipids, redox homeostasis, and energy metabolism. However, the report from Wise et al. suggests that little of the glutamine uptake stimulated by MYC is used for macromolecular synthesis (13) . MYC-induced glutamine catabolism is the reprogramming of mitochondrial metabolism to sustain cellular viability and TCA cycle anaplerosis (13) . The most recent findings reported by Le et al. (21) and Wang et al. (28) have emphasized the metabolic reprogramming controlled by MYC in transformed cells and activated T cells. The latter showed that MYC-driven glutamine catabolism couples with multiple biosynthetic pathways, especially ornithine and polyamine biosynthesis (28) . Interestingly, our current studies show that MYC markedly increased glutamine-derived proline biosynthesis. However, how does this biosynthetic pathway fit into the MYC-driven metabolic reprogramming?
The physiological relationship between glutamine and proline metabolism was observed during the 1970s by Windmueller and Spaeth (29) . In rat small intestine, a rapidly proliferating tissue, glutamine was an important substrate, with a utilization rate nearly two-thirds of that for glucose. Interestingly, proline was a quantitatively important product from glutamine. Similarly, in cultured L-M cells, Stoner and Merchant showed a net increase of free proline accompanying the utilization of glutamine (30) . In the tumor microenvironment, a metabolic commensalism between areas under the varying influence of MYC and HIF-1 or between tumor and stromal cells has been proposed (3, (31) (32) (33) . The metabolic advantage afforded by the increased conversion of glutamine to proline remains unclear, but the conversion of one nonessential amino acid to another for protein synthesis seems unlikely. The previously described metabolic interlock between proline synthesis and pentose phosphate pathway offers an attractive model for understanding the up-regulation of the proline synthetic pathway by MYC (34) (35) (36) .
In summary, we showed the suppression of POX/PRODH by MYC, and demonstrated the effect of this reprogramming on cell proliferation and survival, which makes POX/PRODH a potential target for cancer therapeutics. The regulatory mechanism for the decreased expression of tumor suppressor POX/PRODH in human cancer is in part mediated posttranscriptionally by MYC via miRNA. The metabolic link between glutamine and proline afforded by MYC emphasizes the complexity of tumor metabolism, an area deserving additional studies.
Materials and Methods
Cells and Cell Culture. MYC-inducible human Burkitt lymphoma model P493 cells, PC3 human prostate cancer cells were maintained in RPMI medium 1640 with 10% (vol/vol) FBS.
Additional Methods. Detailed descriptions of methods for real-time RT-PCR analysis, small RNAs transfection, Western blot, luciferase assay, measurement of ROS, apoptosis assay, chromatin immunoprecipitation assay, measurement of intracellular proline levels, measurement of glutamate and GSH, and GC-MS, FT-ICR-MS and NMR studies of [ 13 C, 15 N]-Gln contribution to proline biosynthesis are available in supporting information.
